Has Cristina Cabret-Aymat, MD received payments from drug or device companies?

Yes. Drug and device makers reported $108,372 in general payments to Cristina Cabret-Aymat, MD across 226 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cristina Cabret-Aymat, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cristina Cabret-Aymat, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cristina Cabret-Aymat, MD

Neurology · San Juan, PRNPI 1164659348

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $85,525 of the $108,372 with a category attached, or 78.9%. Lilly USA, LLC accounts for 74.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $40,931 and has fallen 98.9% since, to $461 in 2025. Among neurology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$108,372in general payments, 2019–2025

Across 226 payments — averaging $479.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$80K
Pfizer$20K
Eli Lilly Export S.A. Puerto Rico Branch$6K
Eli Lilly$738
AbbVie$479
Teva Pharmaceuticals USA, Inc.$384
plus $707 from 5 others

What the payments were for

Consulting fees$14,94314%
Speaking & faculty fees$85,52579%
Grants$440%
Travel & lodging$4,2464%
Food & beverage$3,5653%
Education$500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	148	$80,177
Pfizer	9	$19,907
Eli Lilly Export S.A. Puerto Rico Branch	12	$5,980
Eli Lilly	1	$738
AbbVie	21	$479
Teva Pharmaceuticals USA, Inc.	5	$384
PBG Puerto Rico LLC	19	$308
Lundbeck LLC	6	$264
Novartis	2	$89
Amgen	2	$32
Upsher-smith Laboratories LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EMGALITY$29,300
REYVOW$25,150
NURTEC ODT$10,581
AJOVY$238
VYEPTI$118

How this compares

$108,372 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$4,293

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
UbrelvyUbrogepant	232	$263,806
Nurtec OdtRimegepant Sulfate	189	$215,682
Emgality PenGalcanezumab-Gnlm	222	$173,226
ReyvowLasmiditan Succinate	43	$32,291
Ajovy AutoinjectorFremanezumab-Vfrm	36	$26,786
Emgality SyringeGalcanezumab-Gnlm	24	$18,500
Aimovig AutoinjectorErenumab-Aooe	21	$16,018
Eletriptan HbrEletriptan Hydrobromide	45	$5,278
Candesartan Cilexetil	35	$2,423
Memantine Hcl	84	$1,061
Naratriptan Hcl	18	$868
Divalproex Sodium ErDivalproex Sodium	30	$754
Venlafaxine Hcl ErVenlafaxine Hcl	37	$743
Gabapentin	87	$737
Topiramate	50	$662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieUbrelvy	$479	$263,806232 claims
PfizerNurtec Odt	$19,907	$215,682189 claims
Lilly USA, LLCReyvow	$80,177	$32,29143 claims
Upsher-smith Laboratories LLCTopiramate	$14	$66250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →